ECM
PCVX icon

Everence Capital Management’s Vaxcyte PCVX Stock Holding History

Everence Capital Management’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-3,680
Closed -$301K – 825
2024
Q4 		$301K Buy
+3,680
New +$365K 0.02% 578

Other funds holding PCVX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

Everence Capital Management's PCVX Position: Q1 2025 in Review

Everence Capital Management sold out of Vaxcyte (PCVX) in Q1 2025, closing a stake of 3,680 shares — an estimated $301K sold.

Everence Capital Management first reported a position in PCVX in Q4 2024 and held it in 1 quarter. The position peaked at $301K in Q4 2024. 315 funds tracked by Wall St. Rank hold PCVX as of Q1 2025.

  • Everence Capital Management reported no remaining Vaxcyte position as of Q1 2025 after selling out during the quarter.
  • Everence Capital Management sold 3,680 Vaxcyte shares in Q1 2025, an estimated $301K.
  • Everence Capital Management first reported a position in Vaxcyte in Q4 2024 and held it in 1 quarter.
  • Everence Capital Management's Vaxcyte position peaked at $301K in Q4 2024.
  • 315 funds tracked by Wall St. Rank held Vaxcyte as of Q1 2025.

Based on Everence Capital Management's 13F filing for Q1 2025, filed 22 Apr 2025.